A 4-Stage, Open-label, Multicenter Study Including Long-term Extension to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Teduglutide (Primary)
- Indications Short bowel syndrome
- Focus Therapeutic Use
- Sponsors NPS Pharmaceuticals; Shire
- 13 Apr 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.
- 02 Nov 2016 Planned End Date changed from 1 Jan 2018 to 1 Mar 2018.
- 17 Jun 2016 Planned number of patients changed from 10 to 11.